CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...
New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding ...
"I just know that my brain's not right," said Carrie Richardson, 44. "And so, I hate it. I just want it to be normal." At 41, Carrie developed early-onset Alzheimer's disease. The condition is caused ...
Blood-based biomarkers, such as Roche’s pTau181 test, offer a powerful tool for identifying the right patients for Alzheimer’s disease clinical trials early. This October saw a landmark development in ...
Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...
Share on Pinterest A new pill for those genetically at risk for Alzheimer’s has shown benefits in clinical trials. FotografiaBasica/Getty Images Past studies show that genetics can play an important ...
Plasma p-tau217 successfully identified Alzheimer's pathology in several neurodegenerative syndromes. This included disorders not typically associated with Alzheimer's disease, like frontotemporal ...
Researchers developed a "clock" model that based on a single blood test can estimate Alzheimer's symptom onset in cognitively unimpaired adults. The model predicted ...
Families with rare gene mutations that cause Alzheimer's in middle age are giving scientists a unique window on the disease, and a quick way to test potential treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results